www.fdanews.com/articles/176346-arch-therapeutics-issued-notice-of-allowance-for-ac5-surgical-hemostatic-device
Arch Therapeutics Issued Notice of Allowance for AC5 Surgical Hemostatic Device
April 25, 2016
Arch Therapeutics has announced that the U.S. Patent and Trademark Office has issued a notice of allowance related to the company’s AC5 surgical hemostatic device.
The broad-method-of-use patent covers technology for treating damaged extracellular matrix and leaky tight junctions.
The Framingham, Mass.-based company now has received patent allowances from the U.S., Japan, Europe, Canada, Israel, Australia, Hong Kong and China. — Anisa Jibrell